Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

42.07 -1.59 (-3.64%)
Streaming Delayed Price Updated: 1:58 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Natural Gas Prices Are Falling Again. Chinese Indices Are Growing Amid Support From The Central Bank
The Dow Jones Index (US30) was up 0.12% at Monday's stock market close. The S&P 500 Index (US500) was down 0.11%. The NASDAQ Technology Index (US100) closed negative 0.41%. 
Via Talk Markets
Topics Economy Energy Stocks
Exposures Fossil Fuels Interest Rates US Equities
Moderna Nears Its First Breakout In Over A Year After Launching Third Cancer Vaccine Test
Moderna and Merck are now testing their cancer vaccine in patients with another form of skin cancer. 
Via Investor's Business Daily
What's Going On With Moderna Stock On Monday?
Merck's trial with Moderna's V940 for advanced cutaneous squamous cell carcinoma. The neoadjuvant and adjuvant therapy with pembrolizumab, aiming for superior event-free survival. Phase 3 expansion... 
Via Benzinga
Stocks Inch Lower Ahead Of Inflation Data, Gold Takes Breather, Bitcoin's Bull Run Persists: What's Driving Markets Monday?
Wall Street opens week with slight dip as investors exercise caution ahead of February's inflation report. Gold pauses, Bitcoin hits $72,000. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Market Whales and Their Recent Bets on MRNA Options
Via Benzinga
Unpacking the Latest Options Trading Trends in Moderna
Via Benzinga
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart... 
Via Benzinga
Exposures Product Safety
1 (Bad) Reason to Sell Moderna Stock Right Now, and 2 Good Reasons to Buy It
Sometimes bad news is a bad reason to sell. 
Via The Motley Fool
Turnaround Plays: 3 Stocks to Buy for a Major Recovery in 2024
While most companies that change their plans fail, investors should pay attention to these three turnaround stocks poised for recovery. 
Via InvestorPlace
Is Novavax a Buy Now?
The stock has dropped 98% over the past three years. 
Via The Motley Fool
3 Reasons to Buy Moderna Stock
The company can still deliver excellent returns. 
Via The Motley Fool
This Is What Whales Are Betting On Moderna
Via Benzinga
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth. 
Via InvestorPlace
7 F-Rated Stocks to Sell in March 2024
This market is too strong to risk holding F-rated stocks. If you're still seeing these names in your portfolio, it's time to make a move. 
Via InvestorPlace
It’s Time! 3 Failing Biotech Stocks to Sell Right Now
The biotech industry offers investors unique investment opportunities but these three are biotechs to sell. 
Via InvestorPlace
ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential
Here are three ChatGPT stock predictions for the most unpredictable of biotech stocks that might just have 10x potential. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Where Will Moderna Stock Be in 5 Years?
Can Moderna be a good stock to buy if it can no longer count on billions in revenue from its COVID vaccine? 
Via The Motley Fool
Exposures COVID-19
Here's How Much You Would Have Made Owning Moderna Stock In The Last 5 Years
Via Benzinga
Moderna to Present at Upcoming Investor Conferences in March 2024
Via ACCESSWIRE
5 Top Stocks to Buy in March
This basket of growth, income, and value has a little something for everyone. 
Via The Motley Fool
Wall Street's Top 10 Stock Calls This Week - Saturday, March 2
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the week of Feb. 26 through March 1. 
Via Talk Markets
3 Magnificent Growth Stocks to Buy in March
These three stocks have two important common denominators: the same industry and tremendous growth prospects. 
Via The Motley Fool
Got $200? 2 Dividend Stocks to Buy and Hold Forever
Trust these two real estate stocks to be attractively priced and proven performers. 
Via The Motley Fool
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
The futures for these two beaten-down stocks could be brighter than their recent pasts. 
Via The Motley Fool
Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024
Via ACCESSWIRE
Earnings Seasons Score Card: 4 Stock Superstars and 3 That Fell Short
Watch these companies, whose share prices have seen big swings higher or lower after they reported Q4 2023 earnings. 
Via InvestorPlace
Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening
When it comes to cancer, one cannot overestimate the importance of early detection. Especially when it comes to colorectal and endometrial cancer that even big pharma companies don’t have a good track... 
Via Benzinga
Moderna Stock Has 33% Upside, According to 1 Wall Street Analyst
A lot is riding on whether there will be demand for its new vaccines. 
Via The Motley Fool
Surgery Partners Posts Weak Sales, Joins Kosmos Energy, Moderna And Other Big Stocks Moving Lower On Monday
U.S. stocks were slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Shares of Surgery Partners, Inc. (NASDAQ: SGRY) fell sharply during Monday’s session following weak... 
Via Benzinga
Topics Stocks
Exposures US Equities
Block To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.